Dr.LipidDallas said:

Reading about receptor desensitisation and trying to work out which of the effects adapt over time and which do not, because people clearly experience…

Pharmacist here. I want to add the drug interaction perspective on the pharmacology.

Key points from a pharmacokinetic standpoint:

• GLP-1 agonists delay gastric emptying, which can affect Tmax of co-administered oral medications
• Monitor patients on warfarin (INR), levothyroxine (TSH), and oral contraceptives during dose titration
• The albumin-binding mechanism of semaglutide (C-18 fatty acid linker) gives it the ~168-hour half-life that enables weekly dosing
• Steady state is reached at approximately 4-5 weeks after dose initiation or adjustment

Re: the pharmacology specifically — the pharmacology here is well-characterized and the clinical implications are straightforward.

Dr.GastroMayo said:

I want to add the drug interaction perspective on the pharmacology.

No disagreement with Dr.GastroMayo. One condition attached. The mechanism is more central than most summaries suggest. Receptor agonism in the arcuate nucleus activates POMC neurons and inhibits AgRP/NPY signalling, and the downstream MC4R pathway is the same one disrupted in monogenic obesity — convergent genetic evidence that the target is the right one. Peripherally there is glucose-dependent insulin secretion, glucagon suppression and delayed gastric emptying, but the gastric component largely adapts over months while the central effect persists, which is why the durable effect is appetite rather than fullness.

Dr.LipidDallas said:

Reading about receptor desensitisation and trying to work out which of the effects adapt over time and which do not, because people clearly experience…

This is my experience too, for whatever a second data point is worth. The detail I would add is minor and it is already implied above.

From the other side of the consultation, briefly.

Semaglutide structural biology relevant to the pharmacology: semaglutide is a 31-amino acid peptide with 94% homology to native GLP-1(7-36). Three key modifications enable its pharmacokinetic profile:

1. Aib8 substitution: DPP-4 resistance (prevents enzymatic degradation)
2. Arg34 substitution: improved chemical stability
3. C18 fatty diacid at Lys26: albumin binding → long half-life

These three modifications transform a peptide with a 2-minute half-life (native GLP-1) into one with a 168-hour half-life (semaglutide). A masterclass in peptide engineering.